Key Highlights

  • Shares, a penny stock, are trading at $1.90, up 14.46% in Friday's session.
  • The company outlined its planned Investigational New Drug application submission to the FDA for the XRx-026 gout program, expected in the fourth quarter of 2026.
  • XORTX estimates the XRx-026 program addresses a US$700 million annual market opportunity, based on prior peak sales of febuxostat.
  • The company is targeting an NDA submission in approximately one year, subject to completion of its planned two-part XRX-OXY-102 clinical trial.

Planned FDA Filing Advances the Gout Program

XORTX Therapeutics (NASDAQ:XRTX) shares jumped in Friday's session after the company outlined its anticipated Investigational New Drug application submission to the FDA for its XRx-026 gout program, planned for the fourth quarter of 2026. XORTX is a late-stage clinical pharmaceutical company headquartered in Calgary, Alberta, focused on developing therapies for hyperuricemia-related and progressive kidney diseases driven by aberrant purine and uric acid metabolism.

The application describes the company's clinical development plan and its intention to file a New Drug Application following completion of the planned two-part XRX-OXY-102 clinical trial, which is being advanced based on positive and supportive prior clinical trial results and discussions with the FDA.

Company Sizes the Opportunity at Over $700 Million Annually

Based on prior peak net sales for febuxostat, a xanthine oxidase inhibitor that once achieved more than US$450 million in annual sales before receiving a boxed warning for cardiovascular risk, XORTX estimates the XRx-026 program addresses an estimated US$700 million market opportunity per annum. The company's XORLO formulation of oxypurinol is designed to provide patients who cannot tolerate current standard-of-care treatments with a differentiated safety and efficacy profile.

NDA Submission Targeted for Roughly One Year Out

Subject to sufficient funding and timely completion of the XRX-OXY-102 clinical trial, XORTX is targeting an NDA submission in approximately one year, with plans to request a pre-NDA meeting with the FDA and begin pre-commercialization activities in parallel if the trial is successfully completed. The company's broader pipeline also includes programs targeting autosomal dominant polycystic kidney disease and acute kidney injury associated with respiratory virus infections.